There has been considerable interest in identifying the cell-surface receptors that mediate the neurotoxic effects of Aβ oligomers, in part because of the possibility that small molecules targeting these receptors, or the downstream pathways they activate, could be used as therapeutic agents to treat AD. The gene discussed is CD177; the disease is Alzheimer disease.